Clinical TrialsRAPP over-enrolled the ph2a due to greater-than-expected patient demand, and they'll now be presenting data of 30 FOS-patients, suggesting strong interest and potential for the study.
Drug DevelopmentRAP-219 has potential to be best-in-class in refractory focal epilepsy due to its once daily dosing, no drug-drug interactions reported so far, and the safe and well-tolerated profile observed in healthy patients.
Earnings And Financial PerformanceRapport Therapeutics announced their earnings, confirming previously announced development timelines.